Month: January 2023

Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key ObjectivesFY2022 top line revenue expected to end the year at ~$80 million, in line with previously announced revenue guidance FY2023 revenue guidance range set between $90 million and $95 million, ending the new year on a solid path to positive cash flow from operating activities FY2023 operating plan to focus on achieving positive EBITDA1 in the near-term based on commercial business growth and new asset opportunities Scientific Advisory Committee formed to optimize Protocol Amendment for our Phase 1 clinical trial of TH1902 The U.S. Food and Drug Administration (“FDA”) confirmed they will review the Protocol Amendment within thirty days of submissionThis news release constitutes “a designated news release” for the purposes of the Company’s prospectus...

SAN JOSE, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) — Nubeva Technologies (TSX-V: NBVA, OTCQB: NBVAF)(“Nubeva” or the “Company”) announces it has a signed a new three-year contract for seven figures per year with a large global services company for the Company’s Ransomware Reversal solutions. Further details of the contract, customer, and industry remain confidential for security purposes. “After a slight lull in ransomware in the first half of 2022, we are seeing a significant uptick in activity across the globe, attacking organizations of all sizes across all sectors,” said Steve Perkins, CMO, and Head of Product. “This contract is very significant for us because it is with a large multi-national company, and it has the potential to grow over the life of the agreement. It demonstrates that large and global companies value our Ransomware...

WINTER PARK, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) — Alpine Income Property Trust, Inc. (NYSE: PINE) (the “Company”) today announced its 2022 acquisition and disposition activities and provided a corporate update. 2022 Acquisition HighlightsDuring the year ended December 31, 2022, the Company acquired 51 net lease retail properties for a total acquisition volume of $187.4 million, representing a weighted-average going-in cash cap rate of 7.1%. Acquisitions completed during the year had a weighted-average remaining lease term of 8.7 years and approximately 76% of annualized base rents are from a tenant or the parent of a tenant with an investment grade credit rating. During the fourth quarter of 2022, the Company acquired seven net lease retail properties for total acquisition volume of $41.7 million, representing a weighted-average...

WINTER PARK, Fla., Jan. 04, 2023 (GLOBE NEWSWIRE) — CTO Realty Growth, Inc. (NYSE: CTO) (the “Company” or “CTO”) today announced its record 2022 acquisition and disposition activities and provided a corporate update. 2022 Investment HighlightsDuring the year ended December 31, 2022, the Company completed five mixed-use or retail property acquisitions for total value of $314.0 million, representing a weighted-average going-in cash cap rate of 7.5%. During the year ended December 31, 2022, the Company originated structured investments totaling $59.2 million at a weighted-average initial yield of 8.2%. The Company’s $19.0 million loan secured by WaterStar Orlando was repaid in full during the fourth quarter of 2022. The 2022 investments are concentrated in well-located submarkets of Atlanta, Richmond, Dallas, and Houston. Notable...

Immunocore to present at the 41stAnnual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 04 January 2023) Immunocore Holdings Plc (Nasdaq: IMCR), a commercial-stage biotechnology company pioneering the development of a novel class of T cell receptor (TCR) bispecific immunotherapies designed to treat a broad range of diseases, including cancer, autoimmune and infectious diseases, today announced that management will participate in a fireside chat at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for Wednesday, January 11, 2023, at 9:00 a.m. Pacific Standard Time (PST). The presentation will be webcast live during the conference and will be available in the ‘Investors’ section of Immunocore’s website at www.immunocore.com. A replay of the presentation...

PHILADELPHIA, Jan. 04, 2023 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that Lalo Flores, Ph.D., Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 9:45 AM PT. A live webcast of the event will be available on the Events & Presentations page of Century’s website. A replay of the webcast will be archived on the Company’s website for a limited time. About Century Therapeutics Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies....